Lucid Diagnostics Inc. was jeered in its public debut, as the New York-based medical diagnostics technology company's stock opened on the Nasdaq 8.9% below its initial public offering price, and kept falling. The company raised $70.0 million, as it sold 5.0 million shares in its IPO, which priced overnight at $14 a share, at the bottom of the expected range of between $14 and $16 a share. The stock's first trade was at $12.75 at 11:03 a.m. Eastern for 365,210 shares. With about 37 million shares outstanding after the IPO, the first trading price valued the company at about $471.65 million. The stock has dropped further since, and was recently trading down 22.1% at $10.91. The stock's weak opening comes on a day of relatively strong investor interest in IPOs, as the Renaissance IPO ETF (IPO) rallied 2.0% in midday trading while the S&P 500 gained 1.6%.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.